Ignite Creation Date:
2026-03-26 @ 3:17 PM
Ignite Modification Date:
2026-03-31 @ 11:10 AM
Study NCT ID:
NCT07449832
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-03-04
First Post:
2025-12-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Sperm Epigenome in Hodgkin Lymphoma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2026-03-25'}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 50}}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2026-04-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2026-02', 'completionDateStruct': {'date': '2030-05-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2026-02-26', 'studyFirstSubmitDate': '2025-12-03', 'studyFirstSubmitQcDate': '2026-02-26', 'lastUpdatePostDateStruct': {'date': '2026-03-04', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2026-03-04', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2029-11-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Alterations in DNA methylation patterns in spermatozoa', 'timeFrame': 'Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy', 'description': 'Sperm analysis : Methyl-C Capture Sequencing (MCC-seq)'}, {'measure': 'Alterations of histone 3 H3k4me3 retention sites in spermatozoa', 'timeFrame': 'Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy', 'description': 'Sperm analysis : chromatin immunoprecipitation followed by sequencing (ChIP-seq)'}], 'secondaryOutcomes': [{'measure': 'Spermogram exam', 'timeFrame': 'Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy', 'description': 'Spermogram examination'}, {'measure': 'Identification of known environmental factors impacting spermatogenesis', 'timeFrame': 'Month 24 after chemotherapy', 'description': 'Patient questionnaire'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['epigenetic', 'chemotherapy', 'male gametes'], 'conditions': ['Hodgkin Disease Lymphoma']}, 'descriptionModule': {'briefSummary': 'Cancer treatments can have long-term effects on fertility. In men, scientific studies suggest that the process of sperm formation (spermatogenesis) may be disrupted even years after recovery, with potential consequences not only for fertility but also for the health of offspring. The effects of chemotherapy on sperm quality, particularly on DNA packaging (chromatin) and the epigenome, remain poorly understood. Therefore, further in-depth studies are needed to determine whether a history of cancer and chemotherapy treatment may impact the health of children fathered by young male survivors.\n\nWe therefore propose to conduct a clinical study aimed at better understanding the mechanisms by which chemotherapies affect spermatogenesis. The results could provide answers by identifying the effects of these drugs on the fertility of young male cancer patients in the long term and the sperm epigenome indicative of the health of the progeny.', 'detailedDescription': 'Advances in cancer treatments are raising new health questions for young survivors of the disease. Cancer itself and DNA-targeted treatments can have long-term effects on reproductive health. In men, spermatogenesis may remain impaired even years after recovery, with consequences for fertility and the health of offspring. It is important to note that sperm production can recover after cancer remission. However, men are advised to wait at least one year after the end of treatment before attempting natural conception, as gamete quality may influence reproductive capacity and offspring health \\[2\\]. Yet, regardless of the mode of conception (natural or assisted reproduction), the question of whether a history of cancer and its treatment may affect the health of their offspring remains a fundamental issue that has not yet been clearly answered. In-depth studies are needed for this growing population of young cancer survivors who wish to have healthy children.\n\nWhere possible, the use of alkylating agents-known for their long-term systemic harmful effects-is being reduced, and less reprotoxic compounds, such as anthracyclines, are favored. Anthracyclines are widely used to treat various cancers prevalent in young men with a favorable survival prognosis and are classified as weakly reprotoxic (i.e., causing a temporary reduction in sperm count). However, they are suspected of having long-term effects on sperm chromatin and epigenome \\[3\\]. The establishment of the sperm epigenome is a complex process resulting from multiple nuclear events during spermatogenesis, including chromatin remodeling and compaction that occur during spermiogenesis. These represent windows of opportunity for alteration by xenobiotics. Furthermore, genomic regions undergoing chromatin rearrangements may be more vulnerable to alterations; if these regions are located on key genes for embryonic development or fetal programming, they may predict adverse effects on offspring \\[4\\]. In fact, emerging evidence suggests that sperm epigenetic marks could be used clinically to predict fertility and male-mediated developmental toxicity \\[5\\].\n\nHere, we focus on young men with Hodgkin lymphoma (HL), one of the most commonly diagnosed malignant tumors at a young age, with a good prognosis and low risk of relapse, and for which treatment is well characterized using an anthracycline-containing protocol: doxorubicin. This pathology thus represents a large and relevant population of young cancer survivors who will consider parenthood after cancer. Due to interindividual variability, human studies aiming to determine the effects of chemotherapy must be able to compare samples before and after treatment in the same individual. Such published prospective longitudinal studies are rare and often include very few cases, as they require substantial resources, strong links between oncology and reproduction services, and the ability to follow patients over time, even after the end of oncological treatment \\[6\\]. A (non-longitudinal) study of the long-term effects of HL treatments demonstrated persistent abnormalities in chromatin structure and DNA integrity \\[7\\]. In the study proposed here, we will analyze epigenetic modifications in sperm from HL patients and their evolution after chemotherapy. We hypothesize that HL and its treatment induce persistent alterations up to 2 years after remission.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT'], 'maximumAge': '45 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Men aged 18 to 45 years\n* Diagnosed with Hodgkin lymphoma\n* Treatment-naïve to any cytotoxic therapy\n* Whose treatment regimen consists of 4 to 6 cycles of ABVD or BrECADD\n* Beneficiaries of the French social security system\n* Not opposed to participating in research\n\nExclusion Criteria:\n\n* Patient receiving abdominal radiotherapy'}, 'identificationModule': {'nctId': 'NCT07449832', 'acronym': 'SPELH', 'briefTitle': 'Sperm Epigenome in Hodgkin Lymphoma', 'organization': {'class': 'OTHER', 'fullName': 'Rennes University Hospital'}, 'officialTitle': 'Multiparametric Detection and Preventive Approaches of Cancer Treatment-induced Epigenetic Instability in the Male Germline.', 'orgStudyIdInfo': {'id': '35RC24_9822_SPELH'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Epigenetic analysis in semen samples', 'description': '30 men with hodgkin lymphoma will be followed during 24 months in order to search epigenetic modifications in male gametes', 'interventionNames': ['Other: Additional semen samples']}], 'interventions': [{'name': 'Additional semen samples', 'type': 'OTHER', 'description': '5 additional semen samples : before chemotherapy, at month 6, 12, 18 and 24 after chemotherapy. Each sperm sample will be stored in liquid nitrogen and sent to Institut National de la Recherche Scientifique (INRS), Quebec, Canada for epigenetic analysis.', 'armGroupLabels': ['Epigenetic analysis in semen samples']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35033', 'city': 'Rennes', 'country': 'France', 'contacts': [{'name': 'Tony MARCHAND, MD, PhD', 'role': 'CONTACT', 'email': 'tony.marchand@chu-rennes.fr', 'phone': '02 99 28 42 91', 'phoneExt': '+33'}, {'name': 'Célia RAVEL, MD, PhD', 'role': 'CONTACT', 'email': 'celia.ravel@chu-rennes.fr', 'phone': '02 99 26 59 16', 'phoneExt': '+33'}], 'facility': 'Centre Hospitalier Universitaire de Rennes', 'geoPoint': {'lat': 48.11109, 'lon': -1.67431}}], 'centralContacts': [{'name': 'Tony MARCHAND, MD, PhD', 'role': 'CONTACT', 'email': 'tony.marchand@chu-rennes.fr', 'phone': '02 99 28 42 91', 'phoneExt': '+33'}, {'name': 'Célia RAVEL, MD, PhD', 'role': 'CONTACT', 'email': 'celia.ravel@chu-rennes.fr', 'phone': '02 99 26 59 16', 'phoneExt': '+33'}], 'overallOfficials': [{'name': 'Géraldine DELBES, PhD', 'role': 'STUDY_CHAIR', 'affiliation': 'Institut National de la Recherche Scientifique (INRS), Québec, Canada'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Rennes University Hospital', 'class': 'OTHER'}, 'collaborators': [{'name': 'Institut National de la Recherche Scientifique - Centre Armand Frappier Santé Biotechnologie', 'class': 'UNKNOWN'}], 'responsibleParty': {'type': 'SPONSOR'}}}}